Bayer erhält in China Zulassung für Asundexian zur Senkung des Schlaganfallrisikos
- Bayers Asundexian in China als erster Faktor-XIa-Hemmer zur Senkung des Schlaganfallrisikos zugelassen; die Zulassung erfolgte nach prioritärer Prüfung.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on October 26, 2026, and is solely responsible for the information contained therein.